CLINICAL_TRIALS
trial_result
· 2025-09-16
Clinical Trial Update: An BE Study to Compare 10mg & 20mg of IMP4297 Capsules in Healthy Chinese Subjects Under Fasting Condition [Phase 1]
Summary
Phase 1 bioequivalence study comparing 10 mg and 20 mg IMP4297 capsules in healthy Chinese subjects under fasting conditions has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Impact Therapeutics, Inc. | Conditions: Solid Tumor | Phase 1 | Status: COMPLETED